Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,436 | 3 | 96.5% |
| Food and Beverage | $345.22 | 5 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $6,200 | 1 | $0 (2018) |
| GENZYME CORPORATION | $1,736 | 1 | $0 (2020) |
| Seagen Inc. | $1,525 | 2 | $0 (2022) |
| Exelixis Inc. | $244.04 | 2 | $0 (2024) |
| PFIZER INC. | $76.34 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $213.12 | 3 | Exelixis Inc. ($136.78) |
| 2023 | $107.26 | 1 | Exelixis Inc. ($107.26) |
| 2022 | $24.84 | 1 | Seagen Inc. ($24.84) |
| 2021 | $1,500 | 1 | Seagen Inc. ($1,500) |
| 2020 | $1,736 | 1 | GENZYME CORPORATION ($1,736) |
| 2018 | $6,200 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($6,200) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $47.75 | General |
| Category: Oncology | ||||||
| 01/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $136.78 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 01/25/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: Oncology | ||||||
| 02/17/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $107.26 | General |
| Category: Oncology | ||||||
| 06/05/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $24.84 | General |
| 09/03/2021 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 10/28/2020 | GENZYME CORPORATION | JEVTANA (Drug) | Consulting Fee | Cash or cash equivalent | $1,736.00 | General |
| Category: Oncology | ||||||
| 07/20/2018 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Consulting Fee | Cash or cash equivalent | $6,200.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 321 | 720 | $295,569 | $73,510 |
| 2022 | 9 | 363 | 715 | $264,182 | $70,499 |
| 2021 | 4 | 233 | 644 | $238,918 | $68,146 |
| 2020 | 7 | 252 | 529 | $186,650 | $44,814 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 77 | 265 | $120,882 | $29,468 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 70 | 172 | $78,331 | $18,930 | 24.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 99 | $29,031 | $9,365 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 64 | $21,087 | $4,723 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 40 | 59 | $19,405 | $4,396 | 22.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $9,072 | $2,206 | 24.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $7,328 | $1,692 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $6,948 | $1,639 | 23.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 17 | 17 | $3,485 | $1,092 | 31.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 63 | 181 | $72,838 | $19,676 | 27.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 69 | 177 | $71,322 | $19,491 | 27.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 88 | $25,496 | $7,210 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 48 | $14,346 | $3,433 | 23.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 59 | $11,845 | $3,375 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 46 | $13,777 | $3,252 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $12,078 | $3,102 | 25.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $11,481 | $2,964 | 25.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 18 | $10,102 | $2,866 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 16 | 16 | $7,244 | $1,483 | 20.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $4,983 | $1,407 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $5,426 | $1,317 | 24.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 16 | 16 | $3,244 | $924.64 | 28.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 72 | 272 | $103,940 | $30,503 | 29.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 49 | 170 | $65,120 | $18,275 | 28.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 97 | $27,426 | $8,010 | 29.2% |
About Dr. Michael Devitt, M.D
Dr. Michael Devitt, M.D is a Internal Medicine healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2011. The National Provider Identifier (NPI) number assigned to this provider is 1174812010.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Devitt, M.D has received a total of $9,781 in payments from pharmaceutical and medical device companies, with $213.12 received in 2024. These payments were reported across 8 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($9,436).
As a Medicare-enrolled provider, Devitt has provided services to 1,169 Medicare beneficiaries, totaling 2,608 services with total Medicare billing of $256,969. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Charlottesville, VA
- Active Since 03/31/2011
- Last Updated 08/09/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1174812010
Products in Payments
- Xofigo (Drug) $6,200
- JEVTANA (Drug) $1,736
- PADCEV (Biological) $1,576
- CABOMETYX (Drug) $244.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Charlottesville
Dr. James Clark, Md, MD
Internal Medicine — Payments: $403,469
Ellen Volker, Md, MD
Internal Medicine — Payments: $175,175
Dr. Oliver Monfredi, Md, MD
Internal Medicine — Payments: $81,756
Ryan Gentzler, M.d, M.D
Internal Medicine — Payments: $76,633
Dr. Mirnela Byku, Md, MD
Internal Medicine — Payments: $58,728
Jonathan Lindner, Md, MD
Internal Medicine — Payments: $56,108